Clinical significance of the immunostimulatory MHC class i chain-related molecule A and NKG2D receptor on NK cells in pancreatic cancer

Medical Oncology

Volumn 28, Issue 2, 2011, Pages 466-474

  Duan, Xiaohui ^a   Deng, Langmei ^a   Chen, Xiong ^a   Lu, Yebin ^a   Zhang, Qi ^a   Zhang, Kejing ^a   Hu, Yongjun ^a   Zeng, Jie ^a   Sun, Weijia ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Clinical pathology; MICA; NKG2D; Pancreatic cancer; Prognosis; Soluble MICA

Indexed keywords

BINDING PROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1 RELATED MOLECULE A; NATURAL KILLER CELL RECEPTOR NKG2D; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GROWTH; CANCER RISK; CHRONIC PANCREATITIS; CLINICAL FEATURE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NATURAL KILLER CELL; PANCREAS CANCER; PANCREAS RESECTION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; TUMOR IMMUNITY; UPREGULATION;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, PANCREATIC DUCTAL; CELL SEPARATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; KILLER CELLS, NATURAL; MALE; MIDDLE AGED; NEOPLASM STAGING; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; PANCREATIC NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 79960333930     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-010-9480-9     Document Type: Article

References (26)

1. A Jemal, et al. 2007 Cancer statistics 2007 CA Cancer J Clin 57 1 43 66 17237035 10.3322/canjclin.57.1.43
2. F Levi F Lucchini E Negri C La Vecchia 2003 Pancreatic cancer mortality in Europe: the leveling of an epidemic Pancreas 27 2 139 142 12883262 10.1097/00006676-200308000-00006 (Pubitemid 36950725)
3. S Kim K Iizuka HL Aguila IL Weissman WM Yokoyama 2000 In vivo natural killer cell activities revealed by natural killer cell-deficient mice Proc Natl Acad Sci USA 97 6 2731 2736 10694580 10.1073/pnas.050588297 1:CAS:528: DC%2BD3cXitVahs7k%3D (Pubitemid 30159240)
4. HF Pross E Lotzova 1993 Role of natural killer cells in cancer Nat Immunol 12 4-5 279 292 1:CAS:528:DyaK2cXhs1Srsbg%3D (Pubitemid 23297445)
5. MN Aparicio-Pagés HW Verspaget AS Peña CB Lamers 1991 Natural killer cell activity in patients with adenocarcinoma in the upper gastrointestinal tract J Clin Lab Immunol 35 1 27 32 1668287
6. S Bauer, et al. 1999 Activation of NK cells and T cells by NKG2D, a receptor for stress -inducible MICA Science 285 5428 727 729 10426993 10.1126/science.285.5428.727 1:CAS:528:DyaK1MXltVehsro%3D (Pubitemid 29484539)
7. V Groh, et al. 1999 Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB Proc Natl Acad Sci USA 96 12 6879 6884 10359807 10.1073/pnas.96.12.6879 1:CAS:528:DyaK1MXks1Wktro%3D (Pubitemid 29274978)
8. CS Vetter, et al. 2002 Expression of stress-induced MHC class I related chain molecules on human melanoma J Invest Dermatol 118 4 600 605 11918705 10.1046/j.1523-1747.2002.01700.x 1:CAS:528:DC%2BD38Xjt1Cju7g%3D (Pubitemid 34309978)
9. M Jinushi, et al. 2003 Expression and role of MICA and MICB in human hepatocellular carcinomas and their regulation by retinoic acid Int J Cancer 104 3 354 361 12569559 10.1002/ijc.10966 1:CAS:528:DC%2BD3sXhvFyks7Y%3D (Pubitemid 36249818)
10. DH Raulet 2003 Roles of the NKG2D immunoreceptor and its ligands Nat Rev Immunol 3 10 781 790 14523385 10.1038/nri1199 1:CAS:528:DC%2BD3sXoslSgsb0%3D (Pubitemid 37328656)
11. G Eisele, et al. 2006 TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells Brain 129 Pt 9 2416 2425 16891318 10.1093/brain/awl205 (Pubitemid 44522126)
12. NF Watson, et al. 2006 Expression of the stress-related MHC class I chain-related protein MICA is an indicator of good prognosis in colorectal cancer patients Int J Cancer 18 6 1445 1452 10.1002/ijc.21510
13. HR Salih HG Rammensee A Steinle 2002 Cutting edge: down-regulation of MICA on human tumors by proteolytic shedding J Immunol 169 8 4098 4102 12370336 1:CAS:528:DC%2BD38XnvFGnt7s%3D (Pubitemid 35178177)
14. S Holdenrieder, et al. 2006 Soluble MICA in malignant diseases Int J Cancer 118 3 684 687 16094621 10.1002/ijc.21382 1:CAS:528:DC%2BD28XjvFOrtQ%3D%3D (Pubitemid 43076018)
15. V Rebmann, et al. 2007 Soluble MICA as an independent prognostic factor for the overall survival and progression-free survival of multiple myeloma patients Clin Immunol 123 1 114 120 17218152 10.1016/j.clim.2006.11.007 1:CAS:528:DC%2BD2sXjtValtLw%3D (Pubitemid 46401507)
16. CS Vetter W Lieb E-B Brocker JC Becker 2004 Loss of non-classical MHC molecules MIC-A/B expression during progression of uveal melanoma Br J Cancer 91 8 1495 1499 15381927 1:CAS:528:DC%2BD2cXotlCktLo%3D (Pubitemid 39486354)
17. V Groh J Wu C Yee T Spies 2002 Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation Nature 419 6908 734 738 12384702 10.1038/nature01112 1:CAS:528:DC%2BD38XnvVyrt7o%3D (Pubitemid 35177960)
18. A Diefenbach ER Jensen AM Jamieson DH Raulet 2001 Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity Nature 413 6852 165 171 11557981 10.1038/35093109 1:CAS:528:DC%2BD3MXntVOqtrk%3D (Pubitemid 32867877)
19. K Li, et al. 2009 Clinical significance of the NKG2D ligands, MICA/B and ULBP2 in ovarian cancer: high expression of ULBP2 is an indicator of poor prognosis Cancer Immunol Immunother 58 5 641 652 18791713 10.1007/s00262-008- 0585-3 1:CAS:528:DC%2BD1MXit1CitLY%3D
20. M Ohashi, et al. 2005 Adenovirus-mediated interferon gene transfer induces regional direct cytotoxicity and possible systemic immunity against pancreatic cancer Br J Cancer 93 4 441 449 16106250 10.1038/sj.bjc.6602713 1:CAS:528:DC%2BD2MXnvFymtb0%3D (Pubitemid 43080018)
21. N Boissel, et al. 2006 BCR/ABL oncogene directly controls MHC class I chain-related molecule A expression in chronic myelogenous leukemia J Immunol 176 8 5108 5116 16585609 1:CAS:528:DC%2BD28XjtV2gtLk%3D
22. JM Routes, et al. 2005 Adenovirus serotype 5 E1A sensitizes tumor cells to NKG2D-dependent NK cell lysis and tumor rejection J Exp Med 202 11 1477 1482 16314433 10.1084/jem.20050240 1:CAS:528:DC%2BD2MXhtlSqtLnK (Pubitemid 41746594)
23. S Gasser S Orsulic EJ Brown DH Raulet 2005 The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor Nature 436 7054 1186 1190 15995699 10.1038/nature03884 1:CAS:528:DC%2BD2MXovVOgtr4%3D (Pubitemid 41232299)
24. A Märten M von Lilienfeld-Toal MW Büchler J Schmidt 2006 Soluble MIC is elevated in the serum of patients with pancreatic carcinoma diminishing gammadelta T cell cytotoxicity Int J Cancer 119 10 2359 2365 16929491 10.1002/ijc.22186 (Pubitemid 44546956)
25. ES Doubrovina, et al. 2003 Evasion from NK cell immunity by MHC class I chain-related molecules expressing colon adenocarcinoma J Immunol 171 12 6891 6899 14662896 1:CAS:528:DC%2BD3sXpsV2rur0%3D (Pubitemid 37532125)
26. JD Wu, et al. 2004 Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer J Clin Invest 114 4 560 568 15314693 1:CAS:528:DC%2BD2cXmvVelsrk%3D (Pubitemid 39572106)